NITE - ナイトスタ―・セラピュ―ティクス (Nightstar Therapeutics plc)

NITEのニュース

   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha
   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha
   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha

calendar